University of California at Los Angeles (UCLA )
Welcome,         Profile    Billing    Logout  
 22 Trials 
37 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ganz, Patricia A
NCT03025139: Mindfulness Meditation or Survivorship Education in Improving Behavioral Symptoms in Younger Stage 0-III Breast Cancer Survivors (Pathways to Wellness)

Active, not recruiting
3
96
US
Educational Intervention, Education for Intervention, Intervention by Education, Intervention through Education, Intervention, Educational, Laboratory Biomarker Analysis, Meditation Therapy, Meditation, Questionnaire Administration
Jonsson Comprehensive Cancer Center, National Cancer Institute (NCI), National Institutes of Health (NIH)
Cancer Survivor, Early-Stage Breast Carcinoma, Stage 0 Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
02/23
02/24
NCT04705025: Cognitive-Behavioral Stress Management Device for the Treatment of Anxiety and Depressive Symptoms in Patients With Stage I-III Breast or Lung Cancer

Terminated
2
5
US
Cognitive Behavior Therapy, CBT, cognitive therapy, CT, Interview, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
Jonsson Comprehensive Cancer Center, Blue Note Therapeutics
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Lung Non-Small Cell Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8
03/23
03/23
NCT04290897: Oxaloacetate for the Improvement of Cognitive Complaints in Stage 0-IIIA Breast Cancer Survivors

Recruiting
2
24
US
Anhydrous Enol-oxaloacetate, Questionnaire Administration
Jonsson Comprehensive Cancer Center, Breast Cancer Research Foundation, MetVital, Inc.
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Early-Stage Breast Carcinoma, Prognostic Stage 0 Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8
11/25
11/26
NCT04593277: Interactive Survivorship Program for the Improvement of Healthcare Resources in Adolescent and Young Adult Cancer Survivors, INSPIRE-AYA Study

Active, not recruiting
N/A
556
US
Internet Mobile Technology, www-mobile, Internet-Based Intervention, Questionnaire Administration, Supportive Care, Supportive Therapy, Symptom Management, Therapy, Supportive, Informational Intervention
Fred Hutchinson Cancer Center, National Cancer Institute (NCI)
Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Hematopoietic and Lymphoid Cell Neoplasm, Invasive Malignant Neoplasm, Leukemia, Lymphoma, Malignant Solid Neoplasm, Sarcoma, Stage I Colorectal Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Thyroid Gland Carcinoma
12/25
12/25
NRG-CC011, NCT05896189: Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors

Recruiting
N/A
386
US
Arm 1: Computerized Cognitive Training-Global Stimulation Games, Arm 2: Computerized Cognitive Training-Neuroplasticity Games
NRG Oncology, National Cancer Institute (NCI)
Breast Cancer, Cognitive Impairments
02/27
11/27
Cloughesy, Timothy F
NCI-2018-02010, NCT03732352: 18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma

Completed
2
12
US
Fludeoxyglucose F-18, 18FDG, FDG, fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18, Osimertinib, AZD-9291, AZD9291, Mereletinib, Tagrisso, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging
Jonsson Comprehensive Cancer Center, AstraZeneca
EGFR Gene Amplification, EGFR Gene Mutation, Glioblastoma, Recurrent Glioblastoma, Supratentorial Glioblastoma, TP53 Wt Allele
01/24
01/24
NCT03382977: Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

Recruiting
1/2
98
US
VBI-1901, Carmustine, BiCNU, Lomustine, Gleostine
VBI Vaccines Inc.
Glioblastoma Multiforme
07/25
08/25
NCT05664243: A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma

Active, not recruiting
1/2
4
US
Autologous genetically modified gamma-delta T cells, Allogeneic genetically modified gamma-delta T cells
In8bio Inc.
Glioblastoma
12/25
12/25
NCT02101905: Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma

Completed
1
29
US
Laboratory Biomarker Analysis, Lapatinib, GSK572016, GW 2016, GW 572016, GW-572016, GW2016, GW572016, Lapatinib Ditosylate, Tykerb, Pharmacological Study, Therapeutic Conventional Surgery
National Cancer Institute (NCI)
Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Oligodendroglioma, Gliosarcoma, Mixed Glioma, Recurrent Adult Brain Neoplasm, Recurrent Glioblastoma
10/21
10/24
NCT04201873: Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma

Recruiting
1
40
US
Dendritic Cell Tumor Cell Lysate Vaccine, DC tumor cell lysate vaccine, dendritic cell-pulsed tumor cell lysate vaccine, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Placebo Administration, Poly ICLC, Hiltonol, Poly I:Poly C with Poly-L-Lysine Stabilizer, poly-ICLC, PolyI:PolyC with Poly-L-Lysine Stabilizer, Polyinosinic-Polycytidylic Acid Stabilized with Polylysine and Carboxymethylcellulose, Polyriboinosinic-Polyribocytidylic Acid-Polylysine Carboxymethylcellulose, Stabilized Polyriboinosinic/Polyribocytidylic Acid
Jonsson Comprehensive Cancer Center, National Cancer Institute (NCI), Merck Sharp & Dohme LLC, Phase One Foundation, Oncovir, Inc.
Recurrent Glioblastoma
08/25
08/26
Paquette, Ronald
DRAMMATIC, NCT04071457: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Hourglass Jan 2023 - Jun 2023 : From trial for patients with r/r multiple myeloma treated with an IMiD and PI
Recruiting
3
1100
Canada, US
Lenalidomide, CC-5013, Revlimid, Daratumumab/rHuPH20
SWOG Cancer Research Network, National Cancer Institute (NCI), Janssen, LP
Multiple Myeloma
07/29
07/40
NCT00085007: BAY 43-9006 in Treating Patients With Imatinib Mesylate-Resistant Chronic Phase Chronic Myelogenous Leukemia

Active, not recruiting
2
US
sorafenib tosylate
Jonsson Comprehensive Cancer Center, National Cancer Institute (NCI)
Leukemia
 
 
MPN-RC 119, NCT04281498: Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation

Completed
2
6
Canada, US
Ruxolitinib, Enasidenib
John Mascarenhas, Celgene Corporation, Incyte Corporation, Myeloproliferative Neoplasms Research Consortium, National Institutes of Health (NIH), National Cancer Institute (NCI)
Accelerated/Blast-phase Myeloproliferative Neoplasm, Chronic-phase Myelofibrosis, IDH2 Mutation
05/23
05/23
OmitMMF, NCT05256537: Fludarabine and Total Body Irradiation 800 Centigray (cGy) or 1125 cGy For Allogeneic Stem Cell Transplant Using Graft Versus Host Disease Prophylaxis With Post-Transplant Cyclophosphamide and Tacrolimus, Without Mycophenolate Mofetil

Active, not recruiting
2
60
US
Omission of the drug mycophenolate mofetil
Ronald Paquette
Hematologic Neoplasms
09/24
09/24
NCT04224558: Stem Cell Transplantation in Crohn's Disease

Recruiting
1/2
15
US
Mesna, Mesnex, Cyclophosphamide, Cytoxan, Neosar, Filgrastim, Neupogen, Granix, Apheresis catheter placement, Leukapheresis, Fludarabine, Fludara, Methylprednisolone, solu-medrol, Diphenhydramine, Benadryl, Acetaminophen, Tylenol, anti-thymocyte globulin (rabbit), thymoglobulin, lymphocyte immune globulin, ATGAM, Peripheral Blood Stem Cell Infusion
Cedars-Sinai Medical Center
Crohn Disease
01/25
01/25
NCT03751709: Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL

Completed
1
22
US
Blinatumomab, Blincyto, Haplo-Mismatched Cell Therapy (HMCT), HMCT; 'primary DLI; 'microtransplantation'
Cedars-Sinai Medical Center, Amgen
B-Cell Acute Lymphoblastic Leukaemia, ALL, Adult, B-ALL
03/23
11/24
NCT05887167: Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells with Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects with Relapsed/Refractory Hematological Malignancies

Recruiting
1
20
US
autologous hematopoietic stem cells added to planned CAR T
Joshua Sasine, MD, PhD
Hematologic Malignancy, Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Mantle Cell Lymphoma, Multiple Myeloma, Diffuse Large B Cell Lymphoma
12/25
12/26
GeriBMT, NCT05849207: Post-Transplant Cyclophosphamide in Patients Aged >/= 65 Years Undergoing Haploidentical Transplant

Recruiting
1
26
US
Cyclophosphamide
Ronald Paquette
Hematologic Malignancies
07/27
07/28
Rettig, Matthew B
PSMAddition, NCT04720157 / 2020-003968-56: An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC

Jan 2024 - Dec 2024: Primary data from PSMAddition trial for metastatic hormone sensitive prostate cancer
Active, not recruiting
3
1145
Europe, Canada, Japan, US, RoW
177Lu-PSMA-617, 68Ga-PSMA-11, ARDT, ADT
Novartis Pharmaceuticals, Alliance Foundation Trials, LLC., RTOG Foundation, Inc.
Prostatic Neoplasms
07/25
02/26
NCT02881242: Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer

Active, not recruiting
2
14
US
Laboratory Biomarker Analysis, Quality-of-Life Assessment, Quality of Life Assessment, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Mekinist
Jonsson Comprehensive Cancer Center, Stand Up To Cancer, Novartis, Prostate Cancer Foundation
Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
01/24
01/25
CHOMP, NCT04104893: A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation

Recruiting
2
30
US
Pembrolizumab, Keytruda
VA Office of Research and Development, Merck Sharp & Dohme LLC
Metastatic Castration Resistant Prostate Cancer
03/25
12/25
BRACeD, NCT04038502: Carboplatin or Olaparib for BRcA Deficient Prostate Cancer

Recruiting
2
100
US
Carboplatin, Paraplatin, Olaparib, Lynparza
VA Office of Research and Development
Metastatic Castrate Resistant Prostate Cancer, BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L Mutations
08/25
08/25
SNARE, NCT05593497: A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss

Recruiting
2
30
US
Capivasertib, abiraterone acetate
VA Office of Research and Development
High-Risk Prostate Cancer
05/27
08/27
BRCAAway, NCT03012321: Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects

Active, not recruiting
2
70
US
Olaparib, Lynparza, Abiraterone Acetate, Prednisone
Northwestern University, AstraZeneca, National Cancer Institute (NCI)
Prostate Cancer Metastatic Castration-Resistant, Abnormal DNA Repair, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer
12/26
01/27
NCT06084338: Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc

Recruiting
2
60
US
stereotactic ablative radiotherapy, SBRT, Pluvicto, Lu177-PSMA, topical testosterone, androgel
VA Office of Research and Development
Prostate Cancer
11/27
12/28
CaRe, NCT06056791: Study of INKmune in Patients With mCRPC ( Prostate)

Recruiting
1/2
30
US
INKmune
Inmune Bio, Inc.
Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC
05/25
11/25
NCT03386071: Compassionate Use: Progressive Metastatic Castrate Resistant Prostate Cancer; Monotherapy Treatment With Trametinib

No Longer Available
N/A
NA
Trametinib 2 mg
Jonsson Comprehensive Cancer Center, Novartis
Progressive Metastatic Castrate Resistant Prostate Cancer
 
 
NCT05435495: Mechanisms of Resistance to PSMA Radioligand Therapy

Recruiting
N/A
125
US
Single-photon emission computed tomography, SPECT/CT, Blood Draw, Tumor Biopsy, Biopsy
University of California, San Francisco, National Cancer Institute (NCI), Prostate Cancer Foundation
Prostate Cancer
12/25
12/25
NCT06682390: Role of Race in Nutritional Approach in Men on ADT

Recruiting
N/A
70
US
Hypocaloric anti-inflammatory diet
University of California, Los Angeles, National Comprehensive Cancer Network
Prostate Cancer Metastatic Disease
11/25
11/25
Singh, Arun D
INVINCIBLE-3, NCT06263231: A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults with Soft Tissue Sarcomas

Recruiting
3
333
Europe, Canada, US
INT230-6, Eribulin, Trabectedin, Pazopanib
Intensity Therapeutics, Inc., Premier Research Group plc
Sarcoma,Soft Tissue
12/27
12/28
NCT06709014: A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants with Early AD

Recruiting
3
760
US
buntanetap/posiphen, Placebo
Annovis Bio Inc., Prevail Infoworks, Inc
Early Alzheimers Disease
12/27
06/28
AL, NCT05844982: Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 Mg) Intravitreal Implants Vs Observation for Prevention of VA Loss Due to Radiation Retinopathy

Recruiting
3
600
US
Faricimab, fluocinolone acetonide
Jaeb Center for Health Research, National Eye Institute (NEI), National Institutes of Health (NIH), Alimera Sciences, Genentech, Inc.
Radiation Retinopathy, Visual Impairment
12/29
12/29
ARGSARC, NCT05712694: Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects with Leiomyosarcoma

Recruiting
3
300
Canada, US, RoW
ADI PEG20, Pegargiminase, Placebo
Polaris Group
Soft Tissue Sarcoma
12/27
12/27
RINGSIDE, NCT04871282 / 2020-005833-34: A Study of AL102 in Patients With Progressing Desmoid Tumors

Active, not recruiting
2/3
192
Europe, US, RoW
AL102, Placebo
Immunome, Inc.
Desmoid, Desmoid Tumor
10/25
10/26
NCI-2018-01517, NCT03623854: Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma

Completed
2
10
US
Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Relatlimab, BMS-986016, BMS986016, Immunoglobulin G4, Anti-(human Lymphocyte Activation Gene-3 Protein) (Human Heavy Chain), Disulfide with Human Light Chain, Dimer
Jonsson Comprehensive Cancer Center, Bristol-Myers Squibb
Chordoma, Locally Advanced Chordoma, Metastatic Chordoma, Unresectable Chordoma
09/23
09/23
NCT05957367: A Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies

Recruiting
1/2
94
US
DCC-3116, Ripretinib, QINLOCK, DCC-2618
Deciphera Pharmaceuticals, LLC, Pfizer
GIST
03/27
03/29
Ribas, Antonio
NCT01697527: Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies

Active, not recruiting
2
6
US
aldesleukin, IL-2, Proleukin, recombinant human interleukin-2, recombinant interleukin-2, fludarabine phosphate, 2-F-ara-AMP, Beneflur, Fludara, cyclophosphamide, CPM, CTX, Cytoxan, Endoxan, Endoxana, laboratory biomarker analysis, NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL, anti-NY-ESO-1 TCR gene-engineered lymphocytes, anti-NY-ESO-1 TCR retroviral vector-transduced lymphocytes, dendritic cell vaccine therapy, fludeoxyglucose F 18, 18FDG, FDG, positron emission tomography, FDG-PET, PET, PET scan, tomography, emission computed
Jonsson Comprehensive Cancer Center
Malignant Neoplasm
11/25
11/26

Download Options